ProQR Therapeutics NV (PRQR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ProQR Therapeutics NV (PRQR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8266
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ProQR Therapeutics NV (ProQR) is a clinical-stage biotech company that discovers and develops drugs for the treatment of genetic disorders. The company’s lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber’s congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. It develops novel investigational drug called QR-421 for the treatment of usher syndrome, fuchs endothelial corneal dystrophy, dystrophic epidermolysis bullosa, alzheimer’s disease, central nervous system and neuromuscular diseases. The company also offers clinical trial services. It operates through its laboratory and offices located in Leiden. It operates offices in the US and the Netherlands. ProQR is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NV (PRQR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
Licensing Agreements 14
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
Equity Offering 19
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV – Key Competitors 27
ProQR Therapeutics NV – Key Employees 28
ProQR Therapeutics NV – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Strategy And Business Planning 30
Sep 12, 2017: ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics 30
Financial Announcements 31
Aug 08, 2018: ProQR announces financial results for the second quarter of 2018 31
May 09, 2018: ProQR Announces Results for the First Quarter of 2018 32
Feb 28, 2018: ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update 34
Nov 20, 2017: ProQR Announces Results for the Third Quarter of 2017 37
Aug 16, 2017: ProQR Announces Results for the Second Quarter of 2017 39
May 17, 2017: ProQR Announces Results for the First Quarter of 2017 41
Feb 28, 2017: ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update 43
Corporate Communications 46
May 23, 2018: ProQR Appoints Yi-Tao Yu to Its Scientific Advisory Board 46
Nov 09, 2017: ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board 47
Oct 26, 2017: ProQR Announces Management Change and Key Promotions 48
Aug 28, 2017: ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong 49
Mar 27, 2017: ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer 50
Product News 51
Jun 15, 2017: ProQR R&D day Highlights Progress on Pipeline and Introduces Axiomer, a novel proprietary RNA Technology 51
05/01/2017: ProQR to Present Data on QRX-411 at ARVO 53
05/01/2017: ProQR to Present Data on QRX-421 at ARVO 54
Product Approvals 55
Sep 05, 2017: ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 55
Jul 05, 2017: ProQR’s Drug Candidate QRX-411 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA 56
Clinical Trials 57
Oct 24, 2017: ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference 57
Sep 25, 2017: ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis 58
Aug 29, 2017: ProQR Completes Dosing of Cystic Fibrosis Patients in QR-010 Phase 1b Trial 60
Jun 08, 2017: ProQR to present QR-010 data at the European Cystic Fibrosis Society Conference and provides an update on the ongoing Phase 1b trial 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Deals By Therapy Area, 2012 to YTD 2018 9
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ProQR Therapeutics Enters into Agreement with EB Research Partnership and EB Medical Research Foundation 11
Foundation Fighting Blindness and ProQR Therapeutics Enter into Agreement 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 13
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 14
ProQR Therapeutics Enters into Licensing Agreement with Leiden University Medical Center 15
ProQR Therapeutics Enters into Licensing Agreement with Cystic Fibrosis Foundation 16
ProQR Therapeutics Enters into Licensing Agreement with Radboud University Medical Center 17
ProQR Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 18
ProQR Therapeutics Raises USD104.1 Million in Public Offering of Shares 19
Proqr Therapeutics Prices Public Offering of Shares for USD16.1 Million 21
Proqr Therapeutics Prices Private Placement of Shares for USD4.6 Million 22
Amylon Therapeutics Spin Out from ProQR Therapeutics 23
ProQR Therapeutics to Raise USD6 Million in Private Placement of Shares 24
ProQR Therapeutics Raises USD112 Million in IPO 25
ProQR Therapeutics NV, Key Competitors 27
ProQR Therapeutics NV, Key Employees 28
ProQR Therapeutics NV, Other Locations 29
ProQR Therapeutics NV, Subsidiaries 29

List of Figures
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ProQR Therapeutics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ProQR Therapeutics NV (PRQR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tissue Regenix Ltd:企業の製品パイプライン分析
    Summary Tissue Regenix Ltd (Tissue Regenix), a subsidiary of Tissue Regenix Group PLC, is a medical technology company that offers replacement body parts from biological materials by using the dCELL technology platform. The company’s proprietary dCELL technology process is applied in markets such as …
  • Karnataka Power Corporation Ltd-エネルギー分野:企業M&A・提携分析
    Summary Karnataka Power Corporation Limited (KPCL) is a state owned power generating company in Karnataka. It is responsible for development and operation of power plants including hydro, thermal, solar and wind. KPCL supplies power to state owned power distribution companies based on power purchase …
  • Ringier AG:企業の戦略的SWOT分析
    Ringier AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Tianda Pharmaceuticals Ltd (455):企業の財務・戦略的SWOT分析
    Summary Tianda Pharmaceuticals Ltd (Tianda Pharma), a subsidiary of Tianda Group Ltd, is a healthcare supplement product manufacturer that researches, develops, manufactures and markets biotechnology, pharmaceutical and health care products. The company provides products covering various therapeutic …
  • ARxIUM:医療機器:M&Aディール及び事業提携情報
    Summary ARxIUM, formerly Intelligent Hospital Systems Inc, a subsidiary of Van Humbeck Family, is a medical device company that designs and manufactures automated solutions for the hospital pharmacy. The company’s products include RxWorks pro, workflow, inventory management, IV compounding system, h …
  • Aksigorta A.S. (AKGRT):企業の財務・戦略的SWOT分析
    Aksigorta A.S. (AKGRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • 4P-Pharma SAS-製薬・医療分野:企業M&A・提携分析
    Summary 4P-Pharma SAS (4P-Pharma) focuses on the development of novel therapies for the treatment of cancer and inflammatory diseases. The company’s pipeline product portfolio includes new chemical entities, biologics, added value generics and fixed dose combinations. Its pipeline candidates targets …
  • Agenus Inc (AGEN):企業の財務・戦略的SWOT分析
    Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PizzaExpress Limited:企業の戦略・SWOT・財務情報
    PizzaExpress Limited - Strategy, SWOT and Corporate Finance Report Summary PizzaExpress Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Saipem SpA:企業の戦略・SWOT・財務情報
    Saipem SpA - Strategy, SWOT and Corporate Finance Report Summary Saipem SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Covance Inc-製薬・医療分野:企業M&A・提携分析
    Summary Covance Inc (Covance), a subsidiary of LabCorp, is a drug development company that offers contract research and manufacturing services. The company offers a broad range of early-stage and late-stage product development services to pharmaceutical, biotechnology and medical device companies. I …
  • Sekisui House, Ltd.:企業の戦略・SWOT・財務分析
    Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sekisui House, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Glanbia plc:企業のM&A・事業提携・投資動向
    Glanbia plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Glanbia plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Coutts & Co:企業の戦略・SWOT・財務分析
    Coutts & Co - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Protalix BioTherapeutics Inc (PLX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients wi …
  • Soft Tissue Regeneration Inc-医療機器分野:企業M&A・提携分析
    Summary Soft Tissue Regeneration Inc (STR) is a medical device company that develops technology for soft tissue regeneration of the anterior cruciate ligament of the knee. The company concentrates on the application of resorbable polymer scaffold technology to regenerate and repair ligament and tend …
  • The Walt Disney Company:戦略・SWOT・企業財務分析
    The Walt Disney Company - Strategy, SWOT and Corporate Finance Report Summary The Walt Disney Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Harbor MedTech Inc:医療機器:M&Aディール及び事業提携情報
    Summary Harbor MedTech Inc (Harbor MedTech) is a commercial-stage regenerative medicine company that offers tissue regeneration solutions. The company offers Architect, an extracellular collagen matrix used in managing partial and full thickness wounds. Its collagen wound matrix systems are used in …
  • Rezolute Inc (RZLT):製薬・医療:M&Aディール及び事業提携情報
    Summary Rezolute Inc (Rezolute) formerly known as AntriaBio Inc, is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for the treatment of metabolic and orphan diseases. Its pipeline product portfolio includes AB101, a microsphere formulation of …
  • S P Setia Berhad (SPSETIA):企業の財務・戦略的SWOT分析
    S P Setia Berhad (SPSETIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆